Cargando…

Oral Alitretinoin for Patients with Refractory Prurigo

Background: prurigo is a chronic skin disorder associated with a history of chronic pruritus. The pathogenesis of prurigo is largely unknown and the treatment of prurigo is unsatisfactory and challenging. Conventional systemic treatments may be beneficial; however, their possible side effects and po...

Descripción completa

Detalles Bibliográficos
Autores principales: Chung, Bo Young, Um, Ji Young, Kang, Seok Young, Jung, Min Je, Kim, Jin Cheol, Kwak, In-Suk, Park, Chun Wook, Kim, Hye One
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7695266/
https://www.ncbi.nlm.nih.gov/pubmed/33182351
http://dx.doi.org/10.3390/medicina56110599
_version_ 1783615149129596928
author Chung, Bo Young
Um, Ji Young
Kang, Seok Young
Jung, Min Je
Kim, Jin Cheol
Kwak, In-Suk
Park, Chun Wook
Kim, Hye One
author_facet Chung, Bo Young
Um, Ji Young
Kang, Seok Young
Jung, Min Je
Kim, Jin Cheol
Kwak, In-Suk
Park, Chun Wook
Kim, Hye One
author_sort Chung, Bo Young
collection PubMed
description Background: prurigo is a chronic skin disorder associated with a history of chronic pruritus. The pathogenesis of prurigo is largely unknown and the treatment of prurigo is unsatisfactory and challenging. Conventional systemic treatments may be beneficial; however, their possible side effects and possible transient efficacy is still a problem. We aimed to present the clinical course and effect of treatment with alitretinoin on patients with prurigo nodularis initially treated with conventional treatments like oral antihistamine, cyclosporine, and phototherapy. Methods: all the patients had prurigo nodularis refractory to conventional treatment. Their medical records included demographic features, past medical history, duration of disease, and treatment modalities; and the clinical courses of the patients were reviewed for this retrospective study. We evaluated patient pruritus and skin lesions for the duration. Results: we present reports involving 10 patients with refractory prurigo. All the patients in our cases were treated with oral alitretinoin after previous treatments and reported the improvement of skin lesions and pruritus within 2 weeks to 3 months. Conclusions: we suggest that oral alitretinoin may be an effective and well tolerated treatment option for patients with intractable prurigo. Further clinical studies are warranted to confirm the long-lasting efficacy and safety of alitretinoin for treating patients with prurigo.
format Online
Article
Text
id pubmed-7695266
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-76952662020-11-28 Oral Alitretinoin for Patients with Refractory Prurigo Chung, Bo Young Um, Ji Young Kang, Seok Young Jung, Min Je Kim, Jin Cheol Kwak, In-Suk Park, Chun Wook Kim, Hye One Medicina (Kaunas) Article Background: prurigo is a chronic skin disorder associated with a history of chronic pruritus. The pathogenesis of prurigo is largely unknown and the treatment of prurigo is unsatisfactory and challenging. Conventional systemic treatments may be beneficial; however, their possible side effects and possible transient efficacy is still a problem. We aimed to present the clinical course and effect of treatment with alitretinoin on patients with prurigo nodularis initially treated with conventional treatments like oral antihistamine, cyclosporine, and phototherapy. Methods: all the patients had prurigo nodularis refractory to conventional treatment. Their medical records included demographic features, past medical history, duration of disease, and treatment modalities; and the clinical courses of the patients were reviewed for this retrospective study. We evaluated patient pruritus and skin lesions for the duration. Results: we present reports involving 10 patients with refractory prurigo. All the patients in our cases were treated with oral alitretinoin after previous treatments and reported the improvement of skin lesions and pruritus within 2 weeks to 3 months. Conclusions: we suggest that oral alitretinoin may be an effective and well tolerated treatment option for patients with intractable prurigo. Further clinical studies are warranted to confirm the long-lasting efficacy and safety of alitretinoin for treating patients with prurigo. MDPI 2020-11-09 /pmc/articles/PMC7695266/ /pubmed/33182351 http://dx.doi.org/10.3390/medicina56110599 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Chung, Bo Young
Um, Ji Young
Kang, Seok Young
Jung, Min Je
Kim, Jin Cheol
Kwak, In-Suk
Park, Chun Wook
Kim, Hye One
Oral Alitretinoin for Patients with Refractory Prurigo
title Oral Alitretinoin for Patients with Refractory Prurigo
title_full Oral Alitretinoin for Patients with Refractory Prurigo
title_fullStr Oral Alitretinoin for Patients with Refractory Prurigo
title_full_unstemmed Oral Alitretinoin for Patients with Refractory Prurigo
title_short Oral Alitretinoin for Patients with Refractory Prurigo
title_sort oral alitretinoin for patients with refractory prurigo
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7695266/
https://www.ncbi.nlm.nih.gov/pubmed/33182351
http://dx.doi.org/10.3390/medicina56110599
work_keys_str_mv AT chungboyoung oralalitretinoinforpatientswithrefractoryprurigo
AT umjiyoung oralalitretinoinforpatientswithrefractoryprurigo
AT kangseokyoung oralalitretinoinforpatientswithrefractoryprurigo
AT jungminje oralalitretinoinforpatientswithrefractoryprurigo
AT kimjincheol oralalitretinoinforpatientswithrefractoryprurigo
AT kwakinsuk oralalitretinoinforpatientswithrefractoryprurigo
AT parkchunwook oralalitretinoinforpatientswithrefractoryprurigo
AT kimhyeone oralalitretinoinforpatientswithrefractoryprurigo